

## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.usplo.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/695,646	10/29/2003	Peter Aage Frischauf	036249-5001	4079
7590 06/26/2007 MORGAN, LEWIS & BOCKIUS LLP 1111 Pennsylvania Avenue, N.W. Washington, DC 20004		•	EXAMINER	
			WALLENHORST, MAUREEN	
			ART UNIT	PAPER NUMBER
			1743	
	•			
•	•		MAIL DATE	DELIVERY MODE
			06/26/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)
	10/695,646	FRISCHAUF ET AL.
Office Action Summary	Examiner	Art Unit
	Maureen M. Wallenhorst	1743
The MAILING DATE of this communication Period for Reply	appears on the cover sheet with	the correspondence address
A SHORTENED STATUTORY PERIOD FOR RE WHICHEVER IS LONGER, FROM THE MAILING  - Extensions of time may be available under the provisions of 37 CF after SIX (6) MONTHS from the mailing date of this communication  - If NO period for reply is specified above, the maximum statutory pe  - Failure to reply within the set or extended period for reply will, by si Any reply received by the Office later than three months after the n earned patent term adjustment. See 37 CFR 1.704(b).	G DATE OF THIS COMMUNICA R 1.136(a). In no event, however, may a rep n. eriod will apply and will expire SIX (6) MONTH tatute, cause the application to become ABAI	ATION.  ly be timely filed  IS from the mailing date of this communication.  NDONED (35 U.S.C. § 133).
Status		•
Responsive to communication(s) filed on _     This action is <b>FINAL</b> . 2b)     Since this application is in condition for all closed in accordance with the practice und	This action is non-final.  wance except for formal matter	
Disposition of Claims		
4)  Claim(s) 1-35 is/are pending in the applica 4a) Of the above claim(s) is/are with 5)  Claim(s) is/are allowed. 6)  Claim(s) 1-35 is/are rejected. 7)  Claim(s) is/are objected to. 8)  Claim(s) are subject to restriction ar  Application Papers  9)  The specification is objected to by the Example 10) The drawing(s) filed on is/are: a)  Applicant may not request that any objection to Replacement drawing sheet(s) including the control of the	nd/or election requirement.  niner.  accepted or b) objected to by the drawing(s) be held in abeyance rrection is required if the drawing(s)	e. See 37 CFR 1.85(a). is objected to. See 37 CFR 1.121(d).
Priority under 35 U.S.C. § 119		
12) Acknowledgment is made of a claim for fore a) All b) Some * c) None of:  1. Certified copies of the priority docum 2. Certified copies of the priority docum 3. Copies of the certified copies of the priority docum application from the International Bu * See the attached detailed Office action for a	nents have been received. nents have been received in App priority documents have been re reau (PCT Rule 17.2(a)).	olication No eceived in this National Stage
Attachment(s)  1) Notice of References Cited (PTO-892)  2) Notice of Draftsperson's Patent Drawing Review (PTO-948  3) Information Disclosure Statement(s) (PTO/SB/08)  Paper No(s)/Mail Date 10/29/03, 6/23/04.	) Paper No(s)/	nmary (PTO-413) Mail Date ormal Patent Application

Application/Control Number: 10/695,646

Art Unit: 1743

1. Receipt is acknowledged of papers submitted under 35 U.S.C. 119(a)-(d), which papers have been placed of record in the file.

Page 2

2. Claims 1-35 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 1 is indefinite since it is not clear how and when the two steps comprising a calibration and quality control cycle have to be repeated. In other words, do the calibration and quality control steps of a cycle have to be repeated immediately after a previous cycle has been completed, or can a test sample be analyzed by the sensor after a first cycle has been completed but before a second cycle is performed/ repeated? See this same problem in claim 18.

Claim 11 is indefinite since it is not clear how and when the second calibration of the sensor is performed. In other words, does the second calibration of the sensor have to be performed immediately after the quality control step, or can a test sample be analyzed with the sensor after the quality control step but before the second calibration step?

Claim 26 is indefinite since it is not clear how and when the multiple calibration and quality control cycles are performed. In other words, do these cycles have to be performed sequentially one after another, or can the sensor analyze a test sample after a first cycle has been performed but before a second cycle is started?

Claim 35 is indefinite since it is an exact duplicate of claim 9. Both claims 35 and claim 9 depend from claim 1 and recite that the parameter is a blood parameter. Claim 35 should depend from claim 26.

Art Unit: 1743

- 3. This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).
- 4. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

- (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.
- 5. Claims 11-12, 14 and 16-25 are rejected under 35 U.S.C. 102(b) as being anticipated by Enzer et al (US Patent 4,871,439, submitted in the Information Disclosure Statement filed on June 23, 2004).

Enzer et al teach of a method and apparatus for measuring certain parameters in a body fluid such as a blood sample. The apparatus comprises a disposable cartridge or cassette containing sensors for different parameters. The sensors comprise electrodes, and upon insertion of the cartridge into a blood chemistry analysis machine, the electrodes of the sensors connect to an electrode interface on the analysis machine, which selects one of the electrical signals from the sensors and passes the signal to a microprocessor in the machine where it is converted from analog to digital form suitable for analysis, storage and display. The cartridge contains therein containers 14 and 16 for calibration solutions A and B. The calibration solutions A and B

Art Unit: 1743

contain different levels of different parameters therein such as different levels of electrolytes. See lines 50-68 in column 5 and lines 1-51 of column 6 in Enzer et al. The compositions of the two calibrating solutions are chosen so that for each of the parameters measured by the system, a pair of values is obtained that are spaced over the range of permissible values that are measured by the system, thus providing a balanced 2-point calibration of the instrument. In a method of using the apparatus, Enzer et al teach that first, a cartridge containing sensors and calibration solutions therein is inserted into a blood chemistry analyzer. A valve 18 in the cartridge is then controlled to direct the calibration solution A into the sensor assembly so that it entirely fills up the flow channel. After a predetermined time for stabilization, measurements of the various potentials and currents are made and processed by the controller. Next, a predetermined quantity of calibration solution B is pumped into and through the sensor card, while during a certain dwell time, measurements are made. A blood sample is then pumped into the cartridge while analogous measurements are made, and based on the measurements of the blood sample and the stored calibration measurements, the controller generates blood gas/electrolyte values characteristic of the blood sample. Enzer et al teach that the process of calibration and blood analysis may be repeated a number of times either automatically or manually until all of the, calibration solutions A and B in the containers 14 and 16 have been depleted. See lines 20-50 in column 15 and Figures 1 and 2 of Enzer et al.

With regards to claims 11-12, 14 and 16-17, the calibration solution A taught by Enzer et al can be considered a first calibration solution of the sensors in the cartridge since it comprises a reference composition containing a certain parameter level of different parameters. The calibration solution B taught by Enzer et al can be considered a quality control solution for the

Art Unit: 1743

sensors in the cartridge since it contains another reference composition containing certain parameter levels of parameters that are different than the parameter levels used in calibration reference solution A. In addition, calibration solution B is applied to the sensors in the cartridge after the sensors are first calibrated with calibration solution A. Therefore, the quality control of the sensors by calibration solution B is performed on the sensors "as calibrated". Since Enzer et al teach that the process of calibration of the sensors with solutions A and B can be repeated, and instant claim 11 does not specify when the second calibration of the sensor using the same reference materials as were used in the steps of performing the first calibration and quality control is performed (i.e. either immediately after the first cycle of calibration and quality control is performed or after a test blood sample is analyzed), the teaching of Enzer et al anticipates instant claims 11-12, 14 and 16-17.

With regards to apparatus claims 18-25, the apparatus taught by Enzer et al serves to anticipate these claims since it comprises one or more sensors sensitive to parameters in a test blood fluid, reference materials representing at least two different parameter levels of different parameters (i.e. blood gases, electrolytes) in the form of calibration solutions A and B, and a programmable device (i.e. a microcontroller) for controlling the functioning of the apparatus. Since apparatus claims are patentable only based upon the physical components which make up the apparatus and not by the functions or methods they perform, the limitations on lines 7-17 of claim 18 are not given any patentable weight. A recitation with respect to the manner a claimed apparatus is intended to be employed does not differentiate the claimed apparatus from a prior art apparatus satisfying the structural limitations of that claimed. See In re Yabnush, 477 F. 2d 1028, 168, USPQ 530 (CCPA 1971).

Application/Control Number: 10/695,646

Art Unit: 1743

6. Claims 1 and 26 would be allowable if rewritten or amended to overcome the rejection(s) under 35 U.S.C. 112, 2nd paragraph, set forth in this Office action since none of the prior art of record teaches or fairly suggests a method of performing calibration and quality control of a sensor for determining a parameter in a test fluid in which a calibration and quality control cycle is repeated, wherein each cycle comprises the steps of performing at least one calibration of the sensor using a reference material representing a parameter level of the parameter, and performing at least one quality control of the sensor, as calibrated, using another reference material representing another different parameter level of the parameter than used in the calibration step, and wherein in one cycle the reference material used in the quality control step is used in the calibration step of another cycle.

Page 6

- 7. Claims 2-10, 13, 15 and 27-35 would be allowable if rewritten to overcome the rejection(s) under 35 U.S.C. 112, 2nd paragraph, set forth in this Office action and to include all of the limitations of the base claim and any intervening claims for the same reasons as set forth above.
- 8. The prior art made of record and not relied upon is considered pertinent to applicant's disclosure.

Please make note of: Kimball et al who teach of a calibration system for sensors located in a physiologic line, wherein both calibration and quality control of the sensors is performed periodically.

Application/Control Number: 10/695,646

Art Unit: 1743

9.

Any inquiry concerning this communication or earlier communications from the

examiner should be directed to Maureen M. Wallenhorst whose telephone number is 571-272-

1266. The examiner can normally be reached on Monday-Thursday from 6:00 AM to 4:30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Jill Warden, can be reached on 571-272-1267. The fax phone number for the

organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent

Application Information Retrieval (PAIR) system. Status information for published applications

may be obtained from either Private PAIR or Public PAIR. Status information for unpublished

applications is available through Private PAIR only. For more information about the PAIR

system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR

system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Maureen M. Wallenhorst Primary Examiner Art Unit 1743 Påge 7

mmw

June 14, 2007

MAUREEN M. WALLENHORST
PRIMARY EXAMINER
GROUP 1333 (700